Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities  by Pugach, Pavel et al.
Virology 387 (2009) 296–302
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roInefﬁcient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at
low cell surface CCR5 densities
Pavel Pugach a,1, Neelanjana Ray b, Per Johan Klasse a, Thomas J. Ketas a, Elizabeth Michael a,
Robert W. Doms b, Benhur Lee c, John P. Moore a,⁎
a Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY, USA
b Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA
c Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA⁎ Corresponding author.
E-mail address: jpm2003@med.cornell.edu (J.P. Moo
1 Present address: Center for Biomedical Research,
Avenue, New York, NY, USA.
0042-6822/$ – see front matter © 2009 Elsevier Inc. A
doi:10.1016/j.virol.2009.02.044a b s t r a c ta r t i c l e i n f oArticle history:
Received 3 November 2008
Returned to author for revision
17 November 2008
Accepted 13 February 2009





Escape mutantsHIV-1 variants resistant to small molecule CCR5 inhibitors such as vicriviroc (VVC) have modiﬁed Env
complexes that can use both the inhibitor-bound and -free forms of the CCR5 co-receptor to enter target cells.
However, entry via the inhibitor-CCR5 complex is inefﬁcient in some, but not all, cell types, particularly cell
lines engineered to express CCR5. We investigated the effect of increasing CCR5 expression, and hence the
density of the inhibitor-CCR5 complex when a saturating inhibitor (VVC) concentration was present, by using
293-Afﬁnoﬁle cells, in which CCR5 expression is up-regulated by the transcriptional activator, ponasterone.
When CCR5 expression was low, the resistant virus entered the target cells to a lesser extent when VVC was
present than absent. However, at a higher CCR5 level, there was much less entry inhibition at a constant,
saturating VVC concentration. We conclude that the relative decrease in entry of a VVC-resistant virus in
some cell types results from its less efﬁcient use of the VVC-CCR5 complex, and that increasing the CCR5
expression level can compensate for this inefﬁciency.© 2009 Elsevier Inc. All rights reserved.Introduction
The small molecule CCR5 inhibitors represent a new class of
therapy for HIV-1 infection, with the ﬁrst class member (Maraviroc;
MVC) now a licensed drug and a second (Vicriviroc; VVC) in late-
stage trials (Hammer et al., 2006; Kuhmann and Hartley, 2008).
These compounds bind to the CCR5 co-receptor and prevent its use
by HIV-1 during virus–cell fusion. The inhibitory mechanism is non-
competitive or allosteric; insertion of the small molecule into a
cavity located within the transmembrane helices disrupts the
geometry of a multi-point interaction between CCR5 and the HIV-
1 gp120 glycoprotein (Dragic et al., 2000; Seibert et al., 2006;
Tsamis et al., 2003; Watson et al., 2005). That association involves,
at a minimum, the second extracellular loop (ECL-2) and tyrosine-
sulfated N-terminus (Tyr-Nt) of CCR5 binding, respectively, to
elements of the gp120 V3 region and the more conserved bridging
sheet that forms between the C1, C2 and C4 domains after CD4
binding has occurred (Cormier and Dragic, 2002; Huang et al.,
2007).re).
Population Council, 1230 York
ll rights reserved.Although MVC, VVC and related compounds do efﬁciently
suppress HIV-1 replication in cell culture and cause substantial
reductions in plasma viremia, resistant variants can arise over time
both in vitro and in vivo (Marozsan et al., 2005; Ogert et al., 2008;
Trkola et al., 2002; Tsibris et al., 2008; Westby et al., 2007). These
escape mutants are substantially resistant to the selecting com-
pound, and are usually cross-resistant to other members of the
same class (Pugach et al., 2008), although the latter is not always
observed (Westby et al., 2007). The mechanism of resistance
involves acquiring the ability to use the inhibitor-CCR5 complex,
in addition to the free co-receptor, so that the virus can enter its
target cells whether or not an inhibitor is present (Pugach et al.,
2007; Westby et al., 2007). The escape mutants tend to be stable
and ﬁt; they replicate efﬁciently in the presence or absence of the
inhibitor, and they do not rapidly revert to sensitivity when cultured
in its absence in vitro, although the re-emergence of pre-treatment
genetic sequences was seen after discontinuation of therapy in one
infected person (Anastassopoulou et al., 2007; Trkola et al., 2002;
Tsibris et al., 2008; Westby et al., 2007). The genetic pathway to
resistance is complex, but it usually involves the accumulation of
sequence changes in the gp120 V3 region (Baba et al., 2007;
Kuhmann et al., 2004; Ogert et al., 2008; Tsibris et al., 2008; Westby
et al., 2007). However, an alternative genetic pathway to the same
phenotype involves sequence alterations elsewhere in Env, without
changes in the V3 sequence (Marozsan et al., 2005). How gp120
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form of CCR5 is not yet fully understood, but is thought to involve
alterations in the relative usage of the different elements of the
multi-point binding interaction.
The inhibition proﬁles for small molecule CCR5 inhibitors
against resistant viruses are unusual in form and they vary with
the target cell type and virus inoculum (Ogert et al., 2008; Pugach
et al., 2007; Westby et al., 2007). Irrespective of the target cell
type, saturating concentrations of the inhibitors cause essentially
100% inhibition of wild-type HIV-1 isolates, clones or Env-
pseudotyped viruses, allowing the determination of conventional
IC50 and IC90 values. The inhibitors have little or no activity against
in vitro-selected resistant viruses, when the target cells are PBMC.
However, when the same inhibitors are tested against the same
resistant viruses in various CCR5-expressing cell lines, they
generally do cause some inhibition of entry/replication, although
with an unconventional manifestation (Ogert et al., 2008; PugachFig. 1. The maximum percent inhibition of a VVC-resistant Env-pseudotyped viruses varies i
ponasterone concentrations of 0.04, 0.2 or 1 μM, to induce low, intermediate or high levels
expression, was held constant at 100 ng/ml. (A) The cell surface expression of CCR5 was
histogram data are shown for cells treated with medium alone (grey outline), 0.04 μM (light
with medium alone (diamonds), 0.04 μM (triangles), 0.2 μM (squares) or 1 μM ponasterone
infected with the CC101.19 cl.7 (panel B) or D1/85.16 cl.23 (panel C) Env-pseudotyped v
calculated from the level of entry observed in the absence of inhibitors at each ponasterone
were, respectively, 58% and 93% in the absence of ponasterone, 44% and 87% at 40 nM ponast
MPI values derived from the above assays are expressed as a function of the ponasterone coet al., 2007; Westby et al., 2007). Thus, in plots that depict how
entry inhibition varies with the inhibitor concentration, the curves
asymptote to a plateau. Once the plateau is reached, increasing the
inhibitor concentration has no additional effect. The explanation of
the “plateau effect” is that it measures the entry of the resistant
virus via the inhibitor-bound CCR5 relative to the drug-free form;
the more efﬁciently entry occurs via the inhibitor-CCR5 complex,
the lower the plateau height, which is also known as the
Maximum Percent Inhibition (MPI) value (Pugach et al., 2007;
Westby et al., 2007). In extreme cases, entry via the inhibitor–
receptor complex may even be more efﬁcient than via the free
receptor, leading to negative inhibition (Pugach et al., 2007; Tsibris
et al., 2008). Understanding these issues is necessary for
interpretation of clinical resistance to CCR5 inhibitors, which is
usually measured using the commercial Troﬁle assay that relies on
single-cycle infection in a CCR5-expressing, engineered cell line
(Whitcomb et al., 2007). Here, we show that the amount of CCR5nversely with the cell surface CCR5 level. 293-Afﬁnoﬁle cells were treated for 18 h with
of cell surface CCR5, respectively. The concentration of tetracycline, which induces CD4
determined by staining with PE-labeled MAb 2D7 followed by ﬂow cytometry. Raw
grey area), 0.2 μM (dark grey area) or 1 μM ponasterone (black area). (B, C) Cells treated
(circles) were incubated for 1 h with varying concentrations of VVC. The cells were then
irus and luciferase production was measured 48 h later. The extent of inhibition was
concentration (100% entry=0% inhibition). The MPI values for CC101.19 and D1/85.16
erone; 34% and 64% at 200 nM ponasterone; 16% and 24% at 1 μM ponasterone. (D) The
ncentration for D1/85.16 cl.23 (squares) and CC101.19 cl.7 (circles).
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resistance is manifested. We also discuss what factors might inﬂuence
the efﬁciency with which resistant viruses use the inhibitor-CCR5
complex on different cells and in different assays.
Results
The maximum extent of inhibition of a CCR5 inhibitor-resistant virus
varies with the cell surface CCR5 density
Previous studies have shown that the manifestation of resistance
to small molecule CCR5 inhibitors is cell type-dependent; in
particular, the MPI value (plateau height) for CCR5 inhibitor-
resistant viruses varies between target cell types, particularly
between PBMC and cell lines engineered to express CCR5 (Ogert
et al., 2008; Pugach et al., 2007; Westby et al., 2007). One plausible
explanation is that the MPI is inﬂuenced by the cell surface CCR5
concentration. Because cell surface areas differ between cell types, it
is difﬁcult to compare the densities of receptors such as CCR5 based
solely on expression level measurements. To address the relation-
ship between MPI and CCR5 surface density, we therefore used the
293-Afﬁnoﬁle cell line in which the amount of cell surface CCR5 can
be varied via application of different concentrations of the
transcriptional activator, ponasterone (B. Lee, unpublished results).
Under these circumstances, increases in CCR5 expression translate
into increases in receptor density, as the cell surface area is
unchanged. Of note is that without ponasterone induction, 293-
Afﬁnoﬁle cells naturally express low levels of CCR5 that are,
however, sufﬁcient for infection by some HIV-1 and SIV strains (B.
Lee, unpublished results).
The 293-Afﬁnoﬁle cells were treated with three different ponas-
terone concentrations to induce low, intermediate or high levels of cell
surface CCR5, and with a ﬁxed (100 ng/ml) concentration of
tetracycline to induce high-level CD4 expression (B. Lee, unpublished
results). In addition to increasing the overall expression of CCR5,
ponasterone treatment also resulted in a more uniform distribution of
the co-receptor across the cell population (Fig. 1A). Thus, in the
absence of ponasterone, two subpopulations of cells with distinct
levels of CCR5 expression were evident. The lowest ponasterone
concentration increased CCR5 expression in both subpopulations, butFig. 2. Increased CCR5 concentration compensates for the reduced efﬁciency of cell entry b
tetracycline (100 ng/ml) and varying ponasterone concentrations (from 0 to 1 μM). Ent
pseudotyped virus was measured in the presence (open symbols) or absence (closed symbol
1 μM ponasterone (the highest concentration used), in the absence of VVC, was deﬁned as
labeled with the 2D7-PE MAb and analyzed for CCR5 expression by ﬂow cytometry. The resat the higher concentrations the highest-expressing subpopulation
became predominant (Fig. 1A).
To assess the effect of varying the CCR5 expression levels, we
infected the ponasterone-treated cells with the Env-pseudotyped
virus CC101.19 cl.7, in the presence of varying concentrations of VVC.
The CC101.19 isolate was derived from the CC1/85 primary virus
under the selection pressure of the AD101 small molecule CCR5
inhibitor, and is cross-resistant to VVC and other, similar inhibitors
(Pugach et al., 2008).
The resulting MPI values for VVC inhibition of CC101.19 cl.7 varied
inversely with the ponasterone concentration, i.e., with the amount of
CCR5 on the cell surface (Fig. 1B). In other words, the more CCR5 was
present on the target cells, the less that entry of the resistant virus was
inhibited by VVC. At the highest ponasterone (i.e., CCR5) concentra-
tion, the MPI represented ∼15% inhibition, similar to what we
previously observed with the same test virus and inhibitors in
PBMC; the virus is almost completely resistant (Kuhmann et al.,
2004; Pugach et al., 2007). In contrast, in the absence of ponasterone,
the MPI of ∼60% was comparable to that seen with the same virus on
U87-CD4/CCR5 cells (Pugach et al., 2007). The latter cells are the basis
of the commercial Troﬁle assay for CCR5 inhibitor resistance
(Whitcomb et al., 2007). Virtually identical results were obtained
when maraviroc, a different small molecule CCR5 inhibitor, was used
instead of VVC (data not shown).
To determine whether the above observations were unique to the
CC101.19 strain or more generally applicable, we repeated the
experiment but using an Env-pseudotyped virus cloned from the
D1/85.16 isolate. The D1/85.16 virus was also derived from CC1/85
but under the selection pressure of VVC; like CC101.19 it uses the
inhibitor-CCR5 complex for entry (Marozsan et al., 2005; Pugach et al.,
2007). However, D1/85.16 cl.23, unlike CC101.19 cl.7, has no V3
sequence changes, and its genetic route to resistance involves the
acquisition of 3 amino acid substitutions in the gp41 fusion peptide
(Marozsan et al., 2005; Anastassopoulou et al., in press).
The phenotype of D1/85.16 cl.23 was broadly similar to that of
CC101.19 cl.7, in that its resistance to VVC was also dependent on the
CCR5 expression level (Fig. 1C). However, D1/85.16 cl.23 was less
resistant to VVC than CC101.19 cl.7 at low CCR5 concentrations; the
MPI value was 24% with cells treated with high concentrations of
ponasterone, but as high as 93% with untreated cells (Fig. 1C). Fory the resistant virus via the VVC-CCR5 complex. 293-Afﬁnoﬁle cells were treated with
ry of the parental CC1/85 cl.6 (squares) or the resistant CC101.19 cl.7 (circles) Env-
s) of 5 μMVVC. The extent of entry of each Env-pseudotyped virus into cells treated with
100% for normalization purposes. For each data point, an identical sample of cells was
ulting MFI value was plotted against the extent of HIV-1 entry.
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and 40 nM ponasterone, 90% at 200 nM and 85% at 1 μM. Furthermore,
the relationship between the extent of (MPI value) and the CCR5
expression level (ponasterone concentration) was steeper for D1/
85.16 cl.23 than for CC101.19 cl.7 (Fig. 1D). This effect of increased
CCR5 levels was mainly on the extent, and not the potency, of
inhibition; thus, the half-maximal inhibitory concentrations for the
two resistant viruses were in the range 1–10 nM irrespective of the
ponasterone concentration (Figs. 1B, C).
When the ponasterone concentration was titrated to vary the cell
surface CCR5 expression level, the mean ﬂuorescence intensity (MFI)
values derived by staining the cells with the phycoerythrin (PE)-
labeled anti-CCR5MAb 2D7 ranged from ∼16,000 to ∼230,000. Under
the same conditions, we measured entry of the parental (CC1/85 cl.6)
and resistant (CC101.19 cl.7) Env-pseudotyped viruses, in the presence
or absence of a saturating VVC concentration (5 μM) (Fig. 2). The entry
of both viruses was only partially dependent on the CCR5 concentra-
tion in the absence of VVC, although a steady increase occurred at the
higher end of the concentration range, particularly for CC101.19 cl.7.
Thus even when CCR5 concentrations were at the low end of the
expression range, each virus could enter the target cells fairly well
(∼65% of the extent seen at the highest CCR5 level).
When VVC was present, entry of the parental virus was, as
expected, negligible, although it did increase slightly with the
CCR5 expression level. However, the resistant virus was much
more dependent on CCR5 levels when VVC was present; at the
lowest CCR5 expression level, the extent of entry was only 35% of
that seen at the highest (Fig. 2). This observation implies that
entry of the resistant virus via the VVC-CCR5 complex is inefﬁcient
when the CCR5 concentration is at the low end of the titration
range, but that increasing the abundance of VVC-CCR5 complexes
can compensate.
Fusion mediated by mutant Env glycoproteins via the VVC-CCR5 complex
The plateau effect in infection–inhibition assays on CCR5-expres-
sing cell lines arises because the resistant viruses use the inhibitor-Fig. 3. The inefﬁcient use of the VVC-CCR5 complex by a VVC-resistant virus does not affect
lines) Env-pseudotyped viruses were incubated for 1 h with varying concentrations of T-20
(closed symbols) of 5 μM VVC. The cells had been treated medium alone (not shown, for clar
clarity) or 1 μM (squares) to induce varying levels of cell surface CCR5. The curves for CC1/85
lowest ponasterone concentration is shown, for clarity. Therewas no detectable entry of CC1/
relative to that observed in the absence of T-20 (=100%). The data shown were averaged fCCR5 complex less efﬁciently than the free co-receptor; the extent of
entry is therefore reduced when the inhibitor concentration is
sufﬁcient to saturate all the available CCR5 (Pugach et al., 2007;
Westby et al., 2007). We showed earlier that increasing the CCR5
concentration (and hence the quantity of inhibitor-CCR5 complexes
present) compensates for the reduced efﬁciency with which the
inhibitor-CCR5 complex is used (Figs. 1B, C). But why is entry via
inhibitor-bound CCR5 less efﬁcient? HIV-1 co-receptor afﬁnity and
fusion kinetics are directly correlated with each other and inversely
correlated with sensitivity to fusion inhibitors such as T-20, because
the longer the “window period” when the fusion-intermediate
structure of gp41 is exposed to T-20, the less T-20 is required for
inhibition (Reeves et al., 2002). We therefore assessed whether the
reduced efﬁciency of CC101.19 cl.7 Env-mediated entry in the presence
of VVC affected T-20 sensitivity (Fig. 3). The CC101.19 cl.7 Env-
pseudotyped virus was ∼2.5-fold less sensitive to T-20 than the
parental virus in the absence of VVC (IC50=65 nM, compared to
25 nM). This is consistent with the modest difference in T-20
sensitivity (∼2-fold) we observed with the corresponding uncloned
isolates in a PBMC-based replication assay (Pugach et al., 2008).When
VVC was present, it did not affect the inhibition of CC101.19 cl.7 by T-
20, irrespective of the CCR5 concentration on the 293-Afﬁnoﬁle cells
(Fig. 3). Hence, even when the cells expressed low levels of CCR5, a
condition when CC101.19 cl.7 entry was relatively inefﬁcient (Fig. 2),
this did not translate into an inﬂuence on T-20 sensitivity (Fig. 3).
Similar results were obtained using the corresponding, fully infectious
parental and resistant viruses on Tzm-bl cells (data not shown).
We also varied the time of addition of a maximally effective T-20
concentration (10 μM) after CC101.19 cl.7 had been allowed to bind to
the Afﬁnoﬁle cells at 4 °C and then transferred to 37 °C to allow the
fusion events to take place. The time taken for the virus to become
resistant to T-20 (i.e., for the T-20-sensitive conformational changes in
gp41 to be completed) was similar whether VVC was present or not
(data not shown).
Taken together, the above experiments imply that using the VVC-
CCR5 complex for entry does not lead to an increased exposure of the
T-20-sensitive fusion-intermediate structure of gp41, compared to useT-20 sensitivity. The parental CC1/85 cl.6 (dashed line) or resistant CC101.19 cl.7 (solid
and then used to infect 293-Afﬁnoﬁle cells in the presence (open symbols) or absence
ity), or with ponasterone at concentrations of 0.04 μM (circles), 0.2 μM (not shown, for
cl.6 in the absence of VVC were virtually identical to each other, so only the one for the
85 cl.6 in the presence of VVC (not shown). The extent of entry of each virus is expressed
rom three independent experiments.
Fig. 4. Cells expressing VVC-resistant Env do not fuse efﬁciently in the presence of VVC. Env-transfected, β-lactamase-expressing QT6 cells were incubated with CCF2-AM-loaded,
CD4- and CCR5-expressing JC53 cells. Membrane fusion by the parental CC1/85 cl.6 (squares) or the resistant CC101.19 cl.7 (circles) Env glycoproteins was measured in the presence
(open symbols) or absence (closed symbols) of 5 μMVVC. The extent of fusion over time is shown as the blue/green ﬂuorescence ratio normalized for background by dividing by the
ratio obtained with control effector cells that were transfected with a vector that does not express Env.
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VVC appears not to be due to any slowing of the rate of conformation
changes in gp41 subsequent to receptor binding.
As an additional measure of the rate and extent of Env-mediated
membrane fusion activity, we used a cell–cell fusion assay in which
Env-expressing QT6 cells were mixed with CD4/CCR5-expressing
JC53 (HeLa-derived) cells (Reeves et al., 2005). Env proteins from
the parental CC1/85 cl.6 and the CCR5 inhibitor-resistant CC101.19
cl.7 viruses were expressed at similar levels on the transfected QT6
cells (data not shown). Both Env proteins mediated membrane
fusion activity in the absence of VVC, but the maximal extent of
fusion was 2-fold lower for the resistant Env than the parental, and
it took longer for the resistant Env to drive fusion to its half-
maximal level, 2400s vs 1500s for the parental Env (Fig. 4). Hence,
the resistant CC101.19 cl.7 Env is less fusion-competent than the
parental CC1/85 cl.6 Env in this experimental system. This
difference agrees with our previous report that the replication
capacity of CC101.19 cl.7 is less than that of CC1/85 cl.6
(Anastassopoulou et al., 2007).
When the JC53 target cells were treated with 5 μM VVC, the rate
and extent of cell–cell fusionwas reduced to negligible levels, for both
the parental and the resistant Envs. The CC101.19 cl.7 Env is, therefore,
resistant to VVC in a virus-entry assay, but sensitive to it in a cell–cell
fusion assay; under the conditions of the fusion assay, the CC101.19
cl.7 Env glycoproteins use CCR5 inefﬁciently and the VVC-CCR5
complex even more so.
Discussion
We previously reported that the manifestation of resistance to
small molecule CCR5 inhibitors varies with the cell type used to
detect and quantify it (Pugach et al., 2007). Here, we show that
CCR5 density is one of the relevant host cell factors that account for
these differences. The resistant viruses have evolved a way to
recognize the inhibitor-bound conformation of CCR5 while not
losing the ability to interact with the free receptor (Pugach et al.,
2007; Westby et al., 2007). Hence they are not “drug-dependent”,
merely “drug-tolerant”. The acquisition of resistance appears to
involve an alteration in how gp120 binds to CCR5. In engineered cell
lines, the inhibitor-bound and -free forms of CCR5 are not utilized
equally well by resistant viruses (the inhibitor-bound form is, of
course, not recognized at all by wild-type strains). Usually, the
inhibitor-bound form is the less effective receptor conﬁguration, but
there are some rare examples of the converse situation, in which aninhibitor modestly increases entry of a resistant virus (Pugach et al.,
2007; Tsibris et al., 2008).
The differential recognition of the two receptor conﬁgurations
underlies the plateau effect, the partial inhibition that arises when
the resistant viruses are tested using cell lines such as the U87-CD4/
CCR5 cells that form the basis of the commercial Troﬁle assay
(Pugach et al., 2007; Westby et al., 2007; Whitcomb et al., 2007).
Here, the height of the plateau (MPI value) is a quantitative
representation of the differential use of the two CCR5 conﬁgura-
tions; the lower the MPI, the more efﬁciently the inhibitor-CCR5
complex is used and the greater the extent of resistance (Pugach et
al., 2007; Westby et al., 2007). We now show that the MPI value is
an inverse function of the CCR5 cell surface density. Speciﬁcally,
high-level resistance (a low plateau or low MPI value) is observed
only when the target cells express high levels of CCR5. Presumably,
the increased amount of the inhibitor-CCR5 complex compensates
for the decreased entry efﬁciency via this complex compared to the
free co-receptor, allowing the resistant virus to enter cells efﬁciently
in the presence of the inhibitor. Overall, these observations should
further help to understand the resistance proﬁles generated in the
commercial Troﬁle assay (Pugach et al., 2007; Westby et al., 2007;
Whitcomb et al., 2007).
CCR5 cell surface levels are highly variable in the population and
depend on multiple genetic factors, including polymorphisms in the
CCR5 promoter and the expression of its chemokine ligands (Martin
et al., 1998; Trkola et al., 1996). Low CCR5 and high chemokine
levels are associated with slower HIV-1 disease progression rates
(Gonzalez et al., 2005; Reynes et al., 2000). Variation in CCR5 and
chemokine expression may also have implications for the use of
CCR5 inhibitors as therapy, including from the perspective of
resistance development. Our observations suggest that individuals
with low levels of free CCR5 (low CCR5 and/or high chemokine)
may be less likely to develop CCR5 inhibitor-resistant variants,
because the less effective use of the inhibitor-CCR5 complex when
CCR5 expression is low would reduce their replicative ﬁtness.
Paradoxically, however, this factor might increase the chances of
resistance developing by what is the normally unfavorable process
of co-receptor switching to CXCR4 use. Clinical studies of CCR5
inhibitors should therefore take into account CCR5 and chemokine
population genetics when assessing not just the effectiveness of
therapy, but also the rapidity and nature of resistance development.
While what we have observed using engineered, CCR5-expressing
cell lines may not extrapolate completely to the different setting of
natural lymphoid cells, a similar relationship between the extent of
301P. Pugach et al. / Virology 387 (2009) 296–302resistance and the level of CCR5 expression was found in recent
studies that used rapamycin to down-regulate CCR5 in PBMCs
(Heredia et al., 2008). By extension, VVC-resistant strains may not
be capable of efﬁciently infecting macrophages in the presence of
VVC, since CCR5 density is expressed at only low levels on these
cells (Lee et al., 1999). Indeed, neither CC101.19 nor D1/85 can
infect macrophages at a quantiﬁable level whether VVC is present
or not (Pugach et al., 2004) (P. Pugach and J. P. Moore, unpublished
results).
The sensitivity of HIV-1 strains to T-20 correlates inversely with
their fusion kinetics and capacity to interact with co-receptors
expressed at low levels (Abrahamyan et al., 2005; Platt et al., 2007;
Reeves et al., 2002; Taylor et al., 2008). Given that CC101.19 cl.7 enters
cells less efﬁciently at low cell surface CCR5 levels when VVC is
present, we investigated whether this virus would become more
sensitive to T-20 in the presence of VVC, especially at low CCR5
expression levels. However, we found that VVC had no such effect on
the sensitivity of CC101.19 cl.7 to T-20 at any of the CCR5 levels tested
(Fig. 3, and data not shown). One possible explanation for this
observation is that the resistance mutations affect a step(s) in the
fusion process that precedes the T-20-sensitive refolding of Env. For
example, the minimum number of Env-CCR5 complexes required to
form a fusion pore may be greater for the resistant Env, or the
recruitment of sufﬁcient CCR5 molecules into a fusion complex may
occur more slowly; the resistance mutations could affect such Env
functions both when VVC is present and absent, creating differences
between the parental and resistant viruses. Five to eight Env-
receptor complexes have been proposed to be involved in HIV-1
entry (Klasse, 2007; Kuhmann et al., 2000; Magnus et al., 2009;
Sougrat et al., 2007); it is conceivable that this number might be
greater for CCR5 inhibitor-resistant variants. Variation in how CCR5
is recruited into fusion complexes could also explain the different
dependences of the parental and resistant viruses on CCR5 density.
It is also possible that parental and resistant viruses preferentially
use different subsets of CCR5 conformational variants for entry, and
that these CCR5 forms differ in abundance between cell types or, in
the case of the 293-Afﬁnoﬁle cells, with the ponasterone concen-
tration (Fig. 1A) (Anastassopoulou et al., in press).
CCR5 inhibitor resistance was not recapitulated in Env-mediated
cell–cell fusion assays. Thus, VVC signiﬁcantly reduced the membrane
fusion activity of Env glycoproteins from the resistant CC101.19 cl.7
virus. Overall, we conclude that, under the conditions of the fusion
assay, the CC101.19 cl.7 Env glycoproteins must use the VVC-CCR5
complex very inefﬁciently. This contrasts with the resistance of the
same Env proteins in infectivity assays using different cell types,
although the extent of resistance was weak at the lowest CCR5
expression levels. Differences in the total amount or forms of CCR5
and/or Env, or in their localization in rafts and other membrane areas,
between the different assay systems might underlie these observa-
tions. The requirements for the lateral diffusion of CCR5 proteins and
their recruitment into fusion pores, may also differ markedly between
virus–cell and cell–cell fusion systems aswell as between the sensitive
and resistant viruses (see above).
We conclude that the interaction between inhibitor-resistant HIV-
1 Env and CCR5 is more sensitive to decreases in CCR5 expression
levels when an inhibitor such as VVC is present, than not. The resistant
virus does not use the inhibitor-CCR5 complex as efﬁciently as it uses
the free co-receptor. However, under some conditions, for example in
a PBMC-based, multi-cycle virus replication assay, the loss of
efﬁciency does not reduce the maximum degree of entry, which can
even be enhanced. Hence the resistant viruses are ﬁt and do not revert
rapidly to sensitivity when cultured in PBMC in the absence of the
inhibitor (Anastassopoulou et al., 2007; Trkola et al., 2002; Westby et
al., 2007). Complete resistance, as seen in a PBMC assay, occurs only
when CCR5 and Env are present at a high enough density, or are in
suitable conﬁgurations, to compensate for less efﬁcient use of theinhibitor-CCR5 complex; under other circumstances, such as in the
Troﬁle assay, resistance is incomplete, leading to distinct plateaus of
inhibition.
Methods
Reagents and cell lines
The CCR5 inhibitors VVC and MVC were gifts from Dr. Julie Strizki
(Schering-Plough Research Institute, Kenilworth, NJ) and Dr. Chris
Hitchcock (Pﬁzer, Sandwich, UK), respectively. T-20 was provided by
Dr. William Olson (Progenics Pharmaceuticals Inc., Tarrytown, NY).
Tetracycline and ponasterone were purchased from Sigma (St. Louis,
Mo), blasticidin from Invitrogen (Carlsbad, CA). 293-Afﬁnoﬁle cells
were maintained in DMEM (Invitrogen), 10% fetal bovine serum (FBS,
Invitrogen) and 50 μg/ml blasticidin (B. Lee, unpublished results).
Tzm-bl cells were obtained from the NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH. Cells were cultured at
37 °C in an atmosphere containing 5% CO2.
Flow cytometry
293-Afﬁnoﬁle cells were detached with versene 18 h after
treatment with ponasterone (Invitrogen). Samples (1×106 cells)
were then stained with PE-labeled 2D7 antibody (BD Biosciences, San
Jose, CA) for 30 min at 4 °C in the cytometry buffer (phosphate-
buffered saline with 10% FBS). After two washes, the antibody-labeled
cells were analyzed using an LSRII digital cytometer (BD Biosciences).
Overlay of the histograms was performed using the FlowJo software
(Tree Star, Inc., Ashland, OR).
HIV-1 entry assays
293-Afﬁnoﬁle cells were seeded in white 96-well plates at a
density of 5000 cells per well, in 100 μl of medium, 18 h prior to
infection. At this point, 293-Afﬁnoﬁle cells were treated with
varying concentrations of ponasterone and tetracycline. VVC and
MVC (50 μl) were added to the cells 1 h prior to infection. Env-
pseudotyped viruses were made by cotransfection of the pCI-env
and pNLluc-AM plasmids into 293T cells at a 3:1 ratio, using
Lipofectamine 2000 (Invitrogen) according to the manufacturer's
instructions. The pCI-env and pNLluc-AM plasmids were constructed
as described previously (Pugach et al., 2007). Two days post-
transfection, supernatants were passed through a 0.45 μm ﬁlter
and immediately used to infect the 293-Afﬁnoﬁle cells. Luciferase
productionwas quantiﬁed after 48 h , as described previously (Pugach
et al., 2007). To assess T-20 sensitivity, Env-pseudotyped viruses were
incubated for 1 h at 37 °C with varying concentrations of T-20 and
then used to infect 293-Afﬁnoﬁle cells.
HIV-1 Env-mediated fusion assay
Fusion mediated by the parental and CCR5 inhibitor-resistant Env
proteins was determined using a β-lactamase reporter cell–cell fusion
assay, as described previously (Lineberger et al., 2002; Reeves et al.,
2005). Brieﬂy, effector QT6 cells were cotransfected with Env and
codon-optimized β-lactamase-expressing plasmids and infected with
a T7 polymerase-encoding vaccinia virus. At 4 °C, effector cells were
added to HeLa/CD4/CCR5 cells (JC53) loaded with CCF2-AM (an
acetoxymethylester derivative of CCF2 that has a donor ﬂuorophore
(coumarin) linked to an acceptor (ﬂuorescein) by a β-lactam ring),
and then the temperature was shifted immediately to 37 °C. Cell–cell
fusion in this assay can be detected as a shift from green to blue
ﬂuorescence, which indicates cleavage of CCF2 by β-lactamase.
Fluorescence was detected using a ﬂuorometer (FLUOstar OPTIMA,
BMG Labtech). The extent of fusion is expressed as the blue/green
302 P. Pugach et al. / Virology 387 (2009) 296–302ﬂuorescence ratio, which was normalized for background by dividing
by the ratio obtained with control effector cells that were transfected
with a vector that does not express Env.
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